Technologies related to NIAID

Title
Licensing Availability: Methods of Diagnosing and Treating CHAPLE, A Newly Identified Orphan Disease
Ref: E-251-2016-0 | Updated: Sep 7, 2018
Prefusion HPIV F Immunogens and Their Use.
Ref: E-215-2016-0 | Updated: Aug 31, 2018
Inhibition of CD300f Function on Dendritic Cells Promotes Tumor Destruction
Ref: E-257-2016-0 | Updated: Jul 23, 2018
Recombinant LL-SXP-1 and Plasmid Encoding LL-SXP-1 for the Immunodiagnosis of Loa Loa
Ref: E-003-2016-0 | Updated: Jun 7, 2018
CCR9 Knockout Mice
Ref: E-200-2015-0 | Updated: Jun 7, 2018
Amino Acid Substitutions Mutants of Anthrax Protective Antigen, Lethal Factor, and Edema Factor
Ref: E-196-2014-0 | Updated: Jun 7, 2018
RL-5 – Rabbit T Cell Line Derived From a Herpesvirus Ateles-induced Rabbit Tumor From the Inbred Rabbit Line B/J
Ref: E-104-2015-0 | Updated: Jun 7, 2018
HIV-1 Clone Bal.01
Ref: E-040-2014-0 | Updated: Jun 7, 2018
pLAS-1 Plasmid
Ref: E-034-2017-0 | Updated: Jun 7, 2018
Pneumonia Virus of Mice Expression Vector PSynK-PVMJ3666
Ref: E-016-2015-0 | Updated: Jun 7, 2018
Non-invasive Method for Ebola Virus Infection Detection in Great Apes and Other Wildlife Hosts
Ref: E-006-2015-0 | Updated: Jun 7, 2018
Expression, Purification, and Validation of Anthrax Toxin Proteins
Ref: E-201-2015-0 | Updated: Jun 7, 2018
Antigens for Use in Loa Loa Microfilariae Quantitative Immunoassays
Ref: E-230-2014-0 | Updated: Jun 7, 2018
Edema Factor Adenylate Cyclase Variants Having Potencies That Are Highly Dependent On the N-end Rule
Ref: E-737-2013-0 | Updated: Jun 7, 2018
CHO NL4-3 gp160
Ref: E-258-2015-0 | Updated: Jun 7, 2018
HIV-1 MW959 gp140 secreting CHO Cells
Ref: E-259-2015-0 | Updated: Jun 7, 2018
HIV-1 NL4-3 gp120 secreting CHO Cells
Ref: E-260-2015-0 | Updated: Jun 7, 2018
WR (Western Reserve) Strain of Vaccinia Virus with K151E Mutation in A34R Gene
Ref: E-263-2015-0 | Updated: Jun 7, 2018
Polyclonal and Monoclonal Antibodies to Human Eosinophil Major Basic Protein, Eosinophil Peroxidase, Eosinophil Cationic Protein, and Eosinophil-Derived Neurotoxin
Ref: E-286-2014-0 | Updated: Jun 7, 2018
Resurfaced Stabilized Core 3 (RSC3) Protein, Derived Proteins, and DNA Encoding These Proteins: RSC3, RSC3 delta371I, RSC3 delta371I/P363N, RSC3 G367R
Ref: E-236-2016-0 | Updated: Jun 7, 2018
Stabilized Influenza Hemagglutinin Stem Region Trimers and Uses Thereof
Ref: E-066-2014-0 | Updated: Jun 22, 2018
Novel Multivalent Nanoparticle Vaccines
Ref: E-060-2015-0 | Updated: Jun 22, 2018
Mononegavirales Vectors expressing Chimeric Antigens
Ref: E-018-2018-0 | Updated: May 7, 2018
Chlamydial Vaccine Technologies
Ref: E-031-2006-0 | Updated: Mar 28, 2018
Protein Nanoparticles for Antigen Display in Vaccines
Ref: E-005-2017/0 | Updated: Mar 9, 2018
Protein Nanoparticles for Antigen Display in Vaccines
Ref: E-005-2017-0 | Updated: Mar 9, 2018
Enhanced Tissue Clearing Solution, Clearing-Enhanced 3D (Ce3D), Compatible with Advanced Fluorescence Microscopy Imaging
Ref: E-168-2016-0 | Updated: May 15, 2018
Compositions and Methods for Blocking Transmission of Plasmodium
Ref: E-294-2016-0 | Updated: May 16, 2018
Monoclonal Antibody Specific for DNA/RNA Hybrid Molecules
Ref: E-738-2013/0 | Updated: Dec 15, 2017
Human CC Chemokine Receptor CX3CR1 / CMKBRL1 cDNA
Ref: B-037-1995/6 | Updated: Dec 4, 2017
Plasmids Encoding and Producing Anthrax Toxin Proteins
Ref: E-059-2008/0 | Updated: Dec 6, 2017
Regulators of G Protein Signalling (RGS) 1,3,4,5 & 13 cDNAs
Ref: E-283-2001/0 | Updated: Dec 4, 2017
Mouse CCR1 cDNA
Ref: B-012-1998/0 | Updated: Dec 4, 2017
Human CCR3 cDNA
Ref: B-009-1998/0 | Updated: Dec 4, 2017
Human CCR2 cDNA
Ref: B-008-1998/0 | Updated: Dec 4, 2017
Plasmid pNL4-3, HIV Clone For Easy Mutational Changes
Ref: B-005-1999/0 | Updated: Dec 4, 2017
Human FPRL1 / FPR2 cDNA
Ref: B-008-1995/0 | Updated: Dec 4, 2017
Human fMLP Receptor / FPR cDNA
Ref: B-007-1995/0 | Updated: Dec 4, 2017
Human Monocyte Chemoattractant Protein-1 (MCP-1/CCL2) cDNA
Ref: B-005-1995/0 | Updated: Dec 4, 2017
CXCR1 - Human IL-8 Receptor cDNA
Ref: B-004-1995/0 | Updated: Dec 4, 2017
Hybridoma Cell Line 7D4 Producing Monoclonal Anti-mouse CD25 (IL-2 receptor) Antibody
Ref: B-004-1991/0 | Updated: Dec 4, 2017
Hybridoma Cell Line 3C7 Producing Monoclonal Anti-mouse CD25 (IL-2 receptor, alpha chain) Antibody
Ref: B-004-1991/1 | Updated: Dec 4, 2017
Hybridoma Cell Line D7 Producing Monoclonal Anti-mouse Ly-6A/E (Sca-1) Antibody
Ref: B-004-1991/2 | Updated: Dec 4, 2017
Regulator of G Protein Signaling (RGS13) Knock-Out Mouse
Ref: E-181-2008/0 | Updated: Dec 4, 2017
Conformation Dependent Anti-major Outer Membrane Protein (MOMP) Monoclonal Antibody BD5
Ref: E-296-2007/0 | Updated: Dec 4, 2017
Hybridoma Cell Line B6GE1, Monoclonal Antibody to the Specific Peptide-MHC Class II Complex
Ref: B-020-1999/0 | Updated: Dec 4, 2017
Hybridoma Cell Line 25-D1.16 Producing Monoclonal Anti-H-2Kb/SIINFEKL Complex Antibody
Ref: B-006-1999/0 | Updated: Dec 4, 2017
Hybridoma Cell Line 715 Producing Monoclonal Antibody Specific for Murine Leukemia Virus gp70
Ref: B-059-1994/2 | Updated: Dec 4, 2017
Hybridoma Cell Line 500 Producing Monoclonal Antibody Specific for Murine Leukemia Virus gp80
Ref: B-059-1994/1 | Updated: Dec 4, 2017
Hybridoma Cell Line D8H21, Monoclonal Antibody to the Specific Peptide-MHC Class II Complex
Ref: B-021-1999/0 | Updated: Dec 4, 2017
Hybridoma Cell Line 273 Producing Monoclonal Antibody Specific for Murine Leukemia Virus gp70
Ref: B-059-1994/0 | Updated: Dec 4, 2017
Hybridoma Cell Line H9.2B8 Producing Monoclonal Anti-mouse CD51 (Vitronectin receptor, alpha chain) Antibody
Ref: B-004-1991/5 | Updated: Dec 4, 2017
Hybridoma Cell Line G7 Producing Monoclonal Anti-mouse CD90 (Thy-1) Antibody
Ref: B-004-1991/4 | Updated: Dec 4, 2017
Hybridoma Cell Line H1.2F3 Producing Monoclonal Anti-mouse CD69 (Early activation marker) Antibody
Ref: B-004-1991/3 | Updated: Dec 4, 2017
Neutralizing Antibodies to Influenza HA and Their Use and Identification
Ref: E-061-2016-0 | Updated: Jun 22, 2018
Broadly Neutralizing Antibodies Against HIV-1 Directed to the CD4 Binding Site of HIV Envelope Protein
Ref: E-300-2009-0 | Updated: Jun 22, 2018
Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology
Ref: E-120-2013/0 | Updated: Oct 2, 2017
Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology
Ref: E-256-2015/0 | Updated: Feb 27, 2018
Development of a Transferrable Norwalk Virus Epitope and Detector Monoclonal Antibody
Ref: E-101-2013/0 | Updated: Sep 5, 2017
Compounds That Treat Malaria and Prevent Malaria Transmission
Ref: E-283-2009/0 | Updated: Jul 18, 2017
Multimeric Protein Toxins to Target Cells Having Multiple Identifying Characteristics
Ref: E-059-2004/0 | Updated: Jul 6, 2017
Methods for Treating Cerebral Edema and Restoring Blood-Brain Barrier Integrity
Ref: E-202-2015/0 | Updated: Jun 14, 2017
Human-derived Monoclonal Antibody for Treatment of Ebola Virus Infection
Ref: E-045-2015-0 | Updated: Jun 22, 2018
A Second CD4-binding Region of HIV-1 gp120 Critical for Viral Infectivity: New Methods for Treatment and Vaccine Development
Ref: E-230-2015/0 | Updated: May 3, 2017
Compositions and Methods for Detecting Loa loa
Ref: E-140-2015/0 | Updated: Apr 20, 2017
A Full-Length Infectious cDNA Clone of Zika Virus from the 2015 Epidemic in Brazil as a Genetic Platform for Studies of Virus-Host Interactions and Vaccine Development
Ref: E-114-2017/0 | Updated: Apr 10, 2017
N6, A Novel, Broad, Highly Potent HIV-specific Antibody
Ref: E-131-2015/0 | Updated: Mar 15, 2017
AMA1-RON2 Complex-Based Vaccine Against Malaria
Ref: E-066-2013/0 | Updated: Mar 9, 2017
Single-Chain Antibodies Directed to Norovirus GI.1 and GII.4 and Their Use
Ref: E-136-2013-0 | Updated: Mar 1, 2017
Synergistic Internal Ribosomal Entry Site (IRES)—MicroRNA-Based Approach for Attenuation of Flaviviruses and Live Vaccine Development
Ref: E-006-2017/0 | Updated: Mar 1, 2017
Inhibition of Host Heme Oxygenase-1 as an Adjunctive Treatment to Improve the Outcome of Conventional Antibiotic Chemotherapy of Mycobacterium tuberculosis (Mtb) Infection
Ref: E-174-2016-0 | Updated: Jun 22, 2018
CD300b Expression Exacerbates Endotoxemia and Septic Peritonitis
Ref: E-112-2016-0 | Updated: Jun 11, 2018
Zika Virus Vaccines
Ref: E-181-2016/0 | Updated: Feb 28, 2017
Zika Virus Vaccines
Ref: E-181-2016-0 | Updated: Jun 22, 2018
A Human Progenitor Mast Cell Line for Allergic and Fibrotic Research and Therapeutic Screening
Ref: E-270-2016/0 | Updated: Feb 28, 2017
Monoclonal Antibodies that Neutralize Norovirus
Ref: E-226-2011-0 | Updated: May 16, 2018
Polyvalent Influenza Virus-Like Particles (VLPs) and Use as Vaccines
Ref: E-195-2014/0 | Updated: Dec 1, 2016
Use of Roseomonas Species to Treat Eczematous (Atopic Dermatitis) Skin Disease
Ref: E-099-2016-0 | Updated: Oct 27, 2016
Detection and Discrimination of Classical and Atypical L-Type BSE Strains by RT-QuIC
Ref: E-048-2015-0 | Updated: May 7, 2018
Prevention or Treatment of Viral Infections by Inhibition of the Histone Methyltransferases EZH1/2
Ref: E-141-2015/0 | Updated: Aug 10, 2015
Adaptor for Suspending a Cryovial Over a Centrifuge Tube
Ref: E-080-2015/0 | Updated: Jul 1, 2015
Recombinant Paramyxoviruses Expressing Optimized Heterologous Antigens
Ref: E-241-2014/0 | Updated: Jun 27, 2017
Live Attenuated Japanese Encephalitis Virus Vaccine
Ref: E-231-2014/0 | Updated: Jul 1, 2015
CXCR4 Reduction Leads to Enhancement of Engraftment of Hematopoietic Stem Cells
Ref: E-173-2014/0 | Updated: Jul 1, 2015
LRRK2 Inhibitors: Novel Treatment for Intestinal Bowel Disorders
Ref: E-070-2014/0 | Updated: Mar 22, 2016
A Novel Virus-Based Expression System
Ref: E-181-2014/0 | Updated: Aug 18, 2015
The Use of Chimeric Antigen Receptor to Control HIV Infection
Ref: E-212-2014/0 | Updated: Sep 9, 2015
A Novel Fusion Protein for Inhibiting HIV Budding
Ref: E-223-2014-0 | Updated: May 10, 2018
Novel Epstein-Barr Virus Vaccines
Ref: E-531-2013/0 | Updated: Dec 17, 2015
Small Molecule Imaging of Fungi by Positron Emission Tomography Scanning
Ref: E-449-2013-0 | Updated: Feb 13, 2017
Multi-specific Chimeric Antigen Receptors Against HIV
Ref: E-170-2013/0 | Updated: Oct 23, 2017
Recombinant Sulfated HIV Envelope Protein and Methods for Making Protein
Ref: E-067-2012/0 | Updated: Apr 15, 2014
Recombinant Stabilized Prefusion Protein of Respiratory Syncytial Virus for Use as a Subunit Vaccine
Ref: E-081-2013-0 | Updated: Jun 22, 2018
Bispecific Antibodies to Target Latent HIV-1 Infection
Ref: E-071-2012/0 | Updated: Jan 6, 2014
Recombinant NIE Antigen from Strongyloides stercoralis
Ref: E-081-2012/0 | Updated: Nov 13, 2013
Monoclonal Antibodies That Recognize the Human Type I Interferon Receptor and Block Interferon Signaling
Ref: E-527-2013/0 | Updated: Aug 22, 2013
Safer Attenuated Virus Vaccines with Missing or Diminished Latency of Infection
Ref: E-217-2004/0 | Updated: Jul 9, 2013
Live Attenuated RSV Vaccines Based on Codon-Pair Deoptimization
Ref: E-080-2013-0 | Updated: Jun 6, 2013
Novel Vaccine for Prevention and Treatment of Chlamydia Infection
Ref: E-133-2012/0 | Updated: Aug 11, 2015
Transmission-Blocking Malaria Vaccine
Ref: E-222-2012-0 | Updated: May 16, 2018

Pages

Subscribe to Technologies related to NIAID